Ishihara N, Komatsu S, Yano Y, Fujishima Y, et al. Treatment Outcomes of Tyrosine Kinase Inhibitors and Durvalumab Plus Tremelimumab After Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma. Anticancer Res 2025;45:251-260.
PMID: 39740814